Back to top
more

Medpace (MEDP)

(Delayed Data from NSDQ)

$386.34 USD

386.34
292,758

+0.64 (0.17%)

Updated May 31, 2024 04:00 PM ET

After-Market: $386.52 +0.18 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Tirthankar Chakraborty headshot

4 Best Momentum Stocks Worth a Buy Using Driehaus Strategy

by Tirthankar Chakraborty

Stocks like Wingstop (WING), Medpace (MEDP), Comfort Systems USA (FIX) and HCI Group (HCI) have been selected as the momentum picks for the day using the Driehaus strategy.

Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner

by Zacks Equity Research

Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.

Align Technology (ALGN) Gains From Innovation, Global Expansion

by Zacks Equity Research

In the United States, Align Technology (ALGN) is focused on reaching young adults as well as teens and their parents through famous athletes, influencers and fashion designers.

Prestige Consumer (PBH) Q4 Earnings Miss, Operating Margin Falls

by Zacks Equity Research

Prestige Consumer's (PBH) Q4 business suffers from supply chain pressure that impacts its ability to fulfill retailer orders.

Labcorp (LH) to Assess Preeclampsia Risk With New Test

by Zacks Equity Research

Labcorp's (LH) new first-trimester test is the latest addition to its dedication to improving women's health.

Profound Medical (PROF) Adds AI to Prostate Cancer Treatment

by Zacks Equity Research

Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.

Thermo Fisher (TMO) Unveils New Extended Blood Genotyping Array

by Zacks Equity Research

Thermo Fisher's (TMO) new Applied Biosystems Axiom BloodGenomiX Array and Software provide a high-throughput solution for more precise blood matching research.

Here's Why Investors Should Retain QIAGEN (QGEN) Stock Now

by Zacks Equity Research

QIAGEN's (QGEN) solid potential in the NGS platform buoys optimism for investors.

Here's Why You Should Retain Henry Schein (HSIC) Stock for Now

by Zacks Equity Research

Investors are optimistic about Henry Schein (HSIC), owing to strategic acquisitions and potential in Henry Schein One.

Centene (CNC) to Continue Serving Kansas' Medicaid Members

by Zacks Equity Research

Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.

Here's Why You Should Buy Align Technology (ALGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Align Technology (ALGN) led by expansion in new geographies and upbeat guidance.

QIAGEN's (QGEN) QCI Interpret Gets European IVDR Certification

by Zacks Equity Research

QIAGEN's (QGEN) Clinical Insight Interpret is the first NGS interpretation platform approved by IVDR for use in cancer and hereditary applications.

Here's Why You Should Retain Zimmer Biomet (ZBH) Stock for Now

by Zacks Equity Research

Strong procedure recovery and progress on the four-pillar strategy bode well for Zimmer Biomet (ZBH).

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

by Zacks Equity Research

Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.

Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies

by Zacks Equity Research

Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.

Is Janus Henderson Small/Mid Cap Growth Alpha ETF (JSMD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for JSMD

Alcon (ALC) Q1 Earnings Surpass Estimates, Margins Expand

by Zacks Equity Research

Alcon's (ALC) Q1 results reflect substantial growth in its franchises on the back of healthy markets.

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Zacks.com featured highlights Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom

by Zacks Equity Research

Medpace, American Axle, Diebold Nixdorf, Euronet and Omnicom have been highlighted in this Screen of The Week article.

3 Reasons Why Growth Investors Shouldn't Overlook Medpace (MEDP)

by Zacks Equity Research

Medpace (MEDP) is well positioned to outperform the market, as it exhibits above-average growth in financials.

QIAGEN (QGEN) to Enhance Forensics With New Partnership

by Zacks Equity Research

QIAGEN's (QGEN) recent deal advances a novel test for its QIAcuity digital PCR devices. This will enhance forensics by improving the quantification of DNA in human samples.

Insulet (PODD) Q1 Earnings Top, 2024 Revenue View Raised

by Zacks Equity Research

Insulet's (PODD) first-quarter performance benefits from the continued high demand for Omnipod 5.

Swayta Shah headshot

5 Stocks With Upgraded Broker Ratings Worth Investing in Now

by Swayta Shah

Brokers have deeper insights into stocks and macroeconomic factors. So, one should follow broker rating upgrades to pick stocks like Medpace (MEDP), American Axle & Manufacturing (AXL), Diebold Nixdorf (DBD), Euronet (EEFT) and Omnicom (OMC).

Haemonetics (HAE) Q4 Earnings Top Estimates, Margins Expand

by Zacks Equity Research

Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.

Are Medical Stocks Lagging Medpace (MEDP) This Year?

by Zacks Equity Research

Here is how Medpace (MEDP) and Tenet Healthcare (THC) have performed compared to their sector so far this year.